Key result
Recent advancements in heart failure management, including SGLT-2 inhibitors, novel medical devices, and artificial intelligence, have expanded therapeutic options and improved patient outcomes.
Why the study?
Heart failure causes considerable morbidity, mortality, and healthcare expenditure, with many advances emerging in the last decade requiring a concise evidence overview for clinical decision-making.
Answers are grounded in this paper and cite their sources.
This narrative review summarizes recent advancements in heart failure management, highlighting new pharmacological therapies, precision medicine, and AI innovations.
Heart failure is associated with considerable morbidity and mortality, resulting in high healthcare expenditure worldwide. The last decade has witnessed several significant developments and advances in the management of heart failure. To ensure rapid access to a concise overview of existing evidence for clinical decision-making regarding heart failure management, this study aimed to review scientific publications on emerging treatment approaches for heart failure, particularly in the last 10 years. Scientific databases, including PubMed, Scopus, Web of Science, and Cochrane Library, were explored for research articles on the advances in the management of heart failure and its comorbidities. A narrative review approach was employed in this report. Heart failure has multiple etiologies; hence, a critical aspect of its management involves the identification and treatment of the cause, which may include structural defects in the heart or pathologies from other parts of the body. Notable criteria for the classification of heart failure or for risk stratification are classification with the degree of ejection fraction and the New York Heart Association classification of heart failure. Challenges of traditional treatment strategies comprised lack of precision, treatment failure, adverse treatment outcomes, and short survival. In recent years, new drugs have been tested and approved for heart failure management, and some of them are included in the treatment guidelines for heart failure. Furthermore, precision medicine through genome editing and artificial intelligence-based innovations have revolutionized the management of healthcare. However, there are emerging concerns regarding the affordability and accessibility of the new treatment strategies.
No takes yet. Share an insight, caveat, or question.
Saheed E. Sanyaolu (2025) conducted a review in Heart failure. Recent advancements in heart failure management, including SGLT-2 inhibitors, novel medical devices, and artificial intelligence, have expanded therapeutic options and improved patient outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: